152 related articles for article (PubMed ID: 17205478)
1. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.
Flandre P; Marcelin AG; Pavie J; Shmidely N; Wirden M; Lada O; Bernard MC; Molina JM; Calvez V
Antivir Ther; 2005; 10(4):479-87. PubMed ID: 16038473
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant genotype interpretation of resistance to didanosine.
Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
[TBL] [Abstract][Full Text] [Related]
4. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
5. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
Winters MA; Bosch RJ; Albrecht MA; Katzenstein DA;
J Infect Dis; 2003 Aug; 188(4):537-40. PubMed ID: 12898440
[TBL] [Abstract][Full Text] [Related]
7. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.
Assoumou L; Brun-Vézinet F; Cozzi-Lepri A; Kuritzkes D; Phillips A; Zolopa A; Degruttola V; Miller V; Costagliola D;
J Infect Dis; 2008 Aug; 198(4):470-80. PubMed ID: 18598191
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
[TBL] [Abstract][Full Text] [Related]
9. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
[TBL] [Abstract][Full Text] [Related]
10. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
11. T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.
Naugler WE; Yong FH; Carey VJ; Dragavon JA; Coombs RW; Frenkel LM
J Infect Dis; 2002 Feb; 185(4):448-55. PubMed ID: 11865396
[TBL] [Abstract][Full Text] [Related]
12. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.
Winters B; Van Craenenbroeck E; Van der Borght K; Lecocq P; Villacian J; Bacheler L
J Virol Methods; 2009 Dec; 162(1-2):101-8. PubMed ID: 19654022
[TBL] [Abstract][Full Text] [Related]
13. Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure.
Svedhem V; Bergroth T; Lidman K; Sönnerborg A
HIV Med; 2007 Nov; 8(8):504-10. PubMed ID: 17944683
[TBL] [Abstract][Full Text] [Related]
14. E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.
Fourati S; Malet I; Guenzel CA; Soulie C; Maidou-Peindara P; Morand-Joubert L; Wirden M; Sayon S; Peytavin G; Simon A; Katlama C; Benichou S; Calvez V; Marcelin AG
Antiviral Res; 2012 Jan; 93(1):167-74. PubMed ID: 22138483
[TBL] [Abstract][Full Text] [Related]
15. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
17. Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival.
Shepp DH; Ashraf A; Tang IT; Match ME; Millan C; Pergolizzi R
J Med Virol; 1996 Aug; 49(4):303-10. PubMed ID: 8877763
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
19. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.
Hernández-Novoa B; Antela A; Gutiérrez C; Pérez-Molina JA; Pérez-Elías MJ; Dronda F; Moreno A; Casado JL; Page C; Pumares M; Galán JC; Moreno S
HIV Med; 2008 Apr; 9(4):187-91. PubMed ID: 18298579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
